Mandate

Vinge advises Zengun Group AB

July 04, 2019 M&A

Vinge has advised Zengun Group AB (publ) in connection with the acquisition of the Zengun Group and in conjunction with a bond issue.

Vinge has advised Zengun Group AB (publ), in connection with the acquisition of the Zengun Group and in conjunction with a bond issue. The construction group Zengun’s founders have, together with the other owners and senior officers, through Zengun Group AB (publ) (the “Company”) repurchased the shares in Zengun Group Holding AB from Segulah Fund V.

In connection with the acquisition, the Company has issued a secured bond in an amount of MSEK 450. The bond, with an interest amount of MSEK 600, is subject to a variable interest rate of STIBOR 3m + 8 per cent and has a final due date in May 2022. The Company has prepared a prospectus which has been approved by and registered at the Swedish Financial Supervisory Authority in accordance with the Swedish Trading in Financial Instruments Act (1991:980) and will apply for listing of the bond on Nasdaq Stockholm.

Vinge’s team primarily consisted of Magnus Pauli, Frida Bergqvist, Lina André, Gabriella Varga, Camilla Andersson, Anna Åhlberg, Josefine Lanker and Jolinn Uhlin.

Related

Vinge has advised Verisure in connection with its IPO on Nasdaq Stockholm

Vinge has advised Verisure plc (“Verisure”) in connection with its IPO on Nasdaq Stockholm. Following the publication of the prospectus on 29 September 2025, trading in Verisure’s shares commenced today, 8 October 2025.
October 08, 2025

Vinge has acted for Advania on the acquisition of smartvokat

smartvokat GmbH, a German-based consultancy specialising in digital transformation within the legal, risk, and compliance domains, will become part of Advania’s business unit Transformation & Automation.
October 08, 2025

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025